Jobs
-
Altamira Therapeutics said that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a patent covering the formulation of Bentrio bentonite-based nasal spray. Bentrio received 510(k) clearance in… Read more . . .
-
Tiziana Life Sciences announced that it has submitted an IND to the FDA seeking approval for a Phase 2 trial of intranasal foralumab in patients with amyotrophic lateral sclerosis. In November 2024, the company announced… Read more . . .
-
According to DPI developer Iconovo, the company has received a grant worth SEK 670,000 from the EU’s Innowwide initiative, which encourages small and medium-sized EU companies to enter international markets. The grant will fund a market study… Read more . . .
-
Taipei-based inhaled drug developer Asia Scientific Global announced that it has completed a pre-IND meeting with the US FDA regarding its Beta 1 dry powder inhaler, a PDE-5 inhibitor that the company is developing for… Read more . . .
-
BiomX announced that it has raised approximately $12 million from investors including the Cystic Fibrosis Foundation to fund a Phase 2b study of its BX004 inhaled phage cocktail for the treatment of P. aeruginosa lung… Read more . . .
-
According to Silo Pharma, the US Patent and Trademark Office (USPTO) has indicated that it will issue a new patent on March 4, 2025 that will provide protection for Silo’s SPC-15 intranasal ketamine. The company… Read more . . .
-
Tiziana Life Sciences announced that it has contracted with CDMO Renaissance Lakewood for development services related to Tiziana’s intranasal foralumab anti-CD3 monoclonal antibody. According to Tiziana, the project includes optimization of the formulation and development… Read more . . .
-
A group comprised of Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium, and CDMO OXB, has announced the initiation of the Phase 1/2 Lenticlair 1 study of BI 3720931, an inhaled lentiviral vector-based gene therapy… Read more . . .
-
Texas-based Zeteo Biomedical has announced the launch of two new devices for intranasal delivery of dry powders: the CygnusMR multi-dose device and the CygnusSDX single dose disposable device. In 2022, the company announced the launch… Read more . . .
-
Kyorin Pharmaceutical is paying an undisclosed fee for the option to license Japanese development and marketing rights to Cyrano Therapeutics’ CYR intranasal theophylline for the treatment of loss of smell, the companies said. A Phase… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.